ASX:NEU Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Neuren Pharmaceuticals Stock (ASX:NEU) 30 days 90 days 365 days Advanced Chart Get Neuren Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,935 shsAverage VolumeN/AMarket Capitalization$1.68 billionP/E Ratio14.31Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.Read More… Receive NEU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address NEU Stock News HeadlinesHealth Check: Neuren says more patients are staying the course as US Daybue sales liftMay 8 at 1:29 AM | msn.comThis $1.3b biotech is still run out of a spare bedroom in MelbourneApril 24, 2025 | afr.comTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be laughable if it wasn’t putting so many Americans’ financial futures at severe risk… That’s why, with the 100-day mark of Trump’s second term just days away, it’s time to shine a light on what’s really going on, because if you move your money out of the wrong places and into the right ones before it’s too late… …you could be one of the few who profits from this imminent trillion-dollar reset.May 8, 2025 | Porter & Company (Ad)Dr Boreham’s Crucible: Drug-development unicorn Neuren banks on ‘cascade of long-term growth’April 14, 2025 | msn.comMonday's HotCopper Trends: Invictus exploration, Neuren's FDA tick | April 14, 2025April 14, 2025 | msn.comGuess which ASX 200 stock is surging 18% on big newsApril 14, 2025 | msn.comNeuren Pharma shares soar on progress for new drug trialApril 14, 2025 | msn.comWhy Core Lithium, Healius, Neuren, and Reject Shop shares are storming higher todayMarch 27, 2025 | msn.comSee More Headlines NEU Stock Analysis - Frequently Asked Questions How were Neuren Pharmaceuticals' earnings last quarter? Neuren Pharmaceuticals Limited (ASX:NEU) released its quarterly earnings results on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 55.28% and a net margin of 60.67%. What other stocks do shareholders of Neuren Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuren Pharmaceuticals investors own include Oxford Lane Capital (OXLC), Pilbara Minerals (PLS), Sunrise Energy Metals (SRL), Westpac Banking (WBC), FBR (FBR), Embark Early Education (EVO) and Dream Industrial Real Estate Investment Trust (DREUF). Company Calendar Last Earnings2/27/2019Today5/08/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryChemicals Current SymbolASX:NEU CIKN/A Webwww.neurenpharma.com Phone61 3 9092 0480FaxN/AEmployees2,060Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A$0.93 Trailing P/E Ratio14.31 Forward P/E RatioN/A P/E GrowthN/ANet Income$117.29 million Net Margins60.67% Pretax MarginN/A Return on Equity55.28% Return on Assets59.56% Debt Debt-to-Equity RatioN/A Current Ratio25.42 Quick Ratio31.54 Sales & Book Value Annual Sales$193.34 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.46 Book ValueA$1.72 per share Price / BookN/AMiscellaneous Outstanding Shares130,070,000Free FloatN/AMarket Cap$1.68 billion OptionableNot Optionable Beta2.13 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (ASX:NEU) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredNew Global Crisis Threatens U.S. RetirementsA new global crisis has just detonated… fueled by escalating trade wars and aggressive moves by evil foreign p...Premier Gold Co | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.